QUANTIFYING DNA SEQUENCES

• US 20190323074A1
• Filed: 12/19/2017
• Published: 10/24/2019
• Est. Priority Date: 01/05/2017
• Status: Active Application

• Current Assignee: Tervisetehnoloogiate Arenduskeskus As
• Original Assignee: Tervisetehnoloogiate Arenduskeskus As
• Inventors: KRJUTSKOV, Kaarel, KOEL, Mariann, KERE, Juha, SALUMETS, Andres
• Application Number:
  US16/475,512
• Publication Number:
  US 20190323074A1
• Time in Patent Office: Days
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6851 Quantitative amplification
• CPC Class Codes: C12Q 1/6855 Ligating adaptors
• CPC Class Codes: C12Q 1/6862 Ligase chain reaction [LCR]
• CPC Class Codes: C12Q 2521/501 Ligase
• CPC Class Codes: C12Q 2525/155 incorporating/generating a new priming site
• CPC Class Codes: C12Q 2525/161 incorporating target specific and non-target specific sites
• CPC Class Codes: C12Q 2525/179 incorporating arbitrary or random nucleotide sequences
• CPC Class Codes: C12Q 2531/113 PCR
• CPC Class Codes: C12Q 2531/137 Ligase Chain Reaction [LCR]
• CPC Class Codes: C12Q 2533/107 Probe or oligonucleotide ligation
• CPC Class Codes: C12Q 2535/122 Massive parallel sequencing
• CPC Class Codes: C12Q 2537/143 Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
• CPC Class Codes: C12Q 2537/165 Mathematical modelling, e.g. logarithm, ratio
• CPC Class Codes: C12Q 2565/50 Detection characterised by immobilisation to a surface
• CPC Class Codes: C12Q 2600/166 Oligonucleotides used as internal standards, controls or normalisation probes
• CPC Class Codes: C40B 40/06 Libraries containing nucleotides or polynucleotides, or derivatives thereof
• CPC Class Codes: C40B 70/00 Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or bar codes
• CPC Class Codes: G16B 30/20 Sequence assembly
• CPC Class Codes: G16B 40/10 Signal processing, e.g. from mass spectrometry [MS] or from PCR

Abstract

A target DNA sequence (1) is contacted with M_L+M_R ligation oligonucleotides (10, 20) under hybridization conditions. The ligation oligonucleotides (10, 20) comprises a respective UMI (14, 15). A ligating agent ligates together the ligation oligonucleotides (10, 20) while hybridized to the target DNA sequence (1) to form a ligated product (30). The ligated product (30) is amplified by means to amplification primers (40, 50), of which one comprises a sample-specific barcode sequence (55), to form an amplified product (60) comprising two UMIs (65), a sequence of interest (66) and one barcode sequence (68). Amplified products (60) from multiple samples are pooled together, sequenced, demultiplexed and mapped to enable quantification of unique target DNA sequences (1) in the different samples.

Claims

1-18. -18. (canceled)

19. A method for quantifying target deoxyribonucleic acid (DNA) sequences, said method comprising the steps of:

contacting, in each container of N separate containers, N being an integer equal to or larger than two, target DNA sequences, under hybridization conditions, with M_L left ligation oligonucleotides comprising, from a 5′

end to a 3′

end, a sequencing read-1 primer site, a respective first unique molecular identifier (UMI) and a respective sequence complementary to a respective first segment of a target DNA sequence and M_R right ligation oligonucleotides comprising, from a 5′

end to a 3′

end, a respective sequence complementary to a respective second segment of a target DNA sequence, a respective second UMI and a sequencing read-2 primer site, wherein M_L and M_R are each an integer equal to or larger than two, said respective first UMI being different for each of said M_L left ligation oligonucleotides and said respective second UMI being different for each of said M_R right ligation oligonucleotides;

adding, in each container of said N separate containers, a ligating agent capable of ligating together said 3′

end of a left ligation oligonucleotide and said 5′

end of a right ligation oligonucleotide while hybridized to a target DNA sequence to form a ligated product comprising two UMIs and hybridized to said target DNA sequence;

immobilizing, in each container of said N separate containers, said ligated product in complex with said target DNA sequence onto a solid phase having preference for DNA sequences of a length in terms of number of deoxyribonucleotides equal to or larger than a minimum length and removing a supernatant;

amplifying, in each container of said N separate containers, said ligated product in presence of a left amplification primer comprising, from a 5′

end to a 3′

end, a first common sequence and said sequencing read-1 primer site and a right amplification primer comprising, from a 5′

end to a 3′

end, a second common sequence, a barcode sequence and a ligation oligonucleotide binding site complementary to said sequencing read-2 primer site to form an amplified product comprising two UMIs and one barcode sequence;

mixing together the content of said N separate containers;

sequencing at least a respective portion of said amplified products by addition of a sequencing read-1 primer comprising said sequencing read-1 primer site and a sequencing read-2 primer comprising said read-2 primer site to form respective sequence reads comprising at least nucleotide sequences of two UMIs, one barcode sequence and a target DNA sequence;

demultiplexing said sequence reads based on nucleotide sequences of said barcode sequences;

mapping said demultiplexed sequence reads to known DNA sequences based on nucleotide sequences of said target DNA sequence; and

quantifying unique target DNA sequences in said N containers based on said demultiplexed and mapped sequence reads and based on nucleotide sequences of said UMIs.

20. The method according to claim 19, wherein adding said ligating agent comprises adding, in each container of said N containers, a ligase to ligate together said 3′

end of said left ligation oligonucleotide and said 5′

end of said right ligation oligonucleotide while hybridized to said target DNA sequence to form said ligated product.

21. The method according to claim 19, wherein immobilizing said ligated product comprises immobilizing, in each container of said N containers, said ligated product hybridized to said target DNA sequence onto magnetic beads having preference for DNA sequences of a length in terms of number of base pairs equal to or larger than 100 base pairs.

22. The method according to claim 19, wherein amplifying said ligated product comprises performing, in each container of said N containers, 2 to 30 cycles of amplification of said ligated product in presence of said left amplification primer and said right amplification primer to form said amplified product.

23. The method according to claim 22, wherein amplifying said ligated product comprises performing, in each container of said N containers, 10 to 20 cycles of amplification of said ligated product in presence of said left amplification primer and said right amplification primer to form said amplified product.

24. The method according to claim 19, further comprising performing size-based separation of said mixed amplified products from any side-product produced in said amplification.

25. The method according to claim 24, wherein performing said size-based separation comprises:

contacting said mixed amplified product with magnetic beads having preference for double-stranded DNA sequences of a target length interval, wherein a length of said amplified product falls within said target length interval;

separating said magnetic beads from non-bound nucleotide sequences; and

retrieving said amplified product from said magnetic beads.

26. The method according to claim 19, wherein sequencing said at least a portion of said amplified product comprises in situ sequencing said at least a portion of said amplified product immobilized onto a solid support based on said first common sequence and/or said second common sequence using read-1 primer and said read-2 primer.

27. The method according to claim 19, wherein demultiplexing said sequence reads comprises dividing said sequence reads into groups having a same nucleotide sequence of said barcode sequences with at most n mismatches allowed for nucleotide sequences of barcode sequences in a same group, n is zero or one.

28. The method according to claim 19, wherein mapping said demultiplexed sequence reads comprises dividing demultiplexed sequence reads into groups having a same nucleotide sequence of said target DNA sequence with at most m mismatches allowed for nucleotide sequences of target DNA sequences in a same group, m is an integer equal to or larger than 0 but no larger than ten.

29. The method according to claim 28, wherein m is an integer equal to or larger than 0 but no larger than five.

30. The method according to claim 29, wherein quantifying unique target DNA sequences comprises quantifying unique target DNA sequences based on determining a number of target DNA sequences in said N containers having a nucleotide sequence with at most m mismatches, having a nucleotide sequence of said barcode sequence with at most n mismatches and having different combinations of said first UMI and said second UMI.

31. A kit for quantifying target deoxyribonucleic acid (DNA) sequences, said kit comprises:

M_L left ligation oligonucleotides comprising, from a 5′

end to a 3′

end, a sequencing read-1 primer site, a respective first unique molecular identifier (UMI) and a respective sequence complementary to a respective first segment of a target DNA sequence;

M_R right ligation oligonucleotides comprising, from a 5′

end to a 3′

end, a respective sequence complementary to a respective second segment of a target DNA sequence, a respective second UMI and a sequencing read-2 primer site, wherein M_L and M_R are each an integer equal to or larger than two, said respective first UMI being different for each of said M_L left ligation oligonucleotides and said respective second UMI being different for each of said M_R right ligation oligonucleotides;

a left amplification primer comprising, from a 5′

end to a 3′

end, a first common sequence and said sequencing read-1 primer site;

a right amplification primer comprising, from a 5′

end to a 3′

end, a second common sequence, a barcode sequence and a ligation oligonucleotide binding site complementary to said sequencing read-2 primer site;

a sequencing read-1 primer comprising said sequencing read-1 primer site; and

a sequencing read-2 primer comprising said read-2 primer site.

32. The kit according to claim 31, further comprising a ligating agent capable of ligating together said 3′

end of a left ligation oligonucleotide and said 5′

end of a right ligation oligonucleotide while hybridized to a target DNA sequence to form a ligated product comprising two UMIs and hybridized to said target DNA sequence.

33. The kit according to claim 32, wherein said ligating agent is a ligase.

34. The kit according to claim 31, further comprising a solid phase having preference for DNA sequences of a length in terms of number of deoxyribonucleotides equal to or larger than a minimum length.

35. The kit according to claim 31, wherein said 5′

end of said M_R right ligation oligonucleotides comprises a 5′

phosphate group.

36. The kit according to claim 31, wherein said first UMI and said second UMI are each a random n₁n₂n₃ . . . n_k sequence, wherein n_i, i=1 . . . k, is one of A, T, C and G, and k is from 2 up to 6.

37. The kit according to claim 36, wherein k is from 3 up to 5.

38. The kit according to claim 37, wherein k is 4.

39. The kit according to claim 31, wherein said barcode sequence is a P nucleotides sample-specific barcode sequence, wherein P is from 4 up to 16.

40. The kit according to claim 39, wherein P is from 4 up to 10.

41. The kit according to claim 40, wherein P is from 6 up to 8.

42. The kit according to claim 41, wherein P is 6.

43. The kit according to claim 31, wherein

said first common sequence is one of a P5 sequence 5′

-AATGATACGGCGACCACCGA-3′

(SEQ ID NO;

     1) and a P7 sequence 5′

-CAAGCAGAAGACGGCATACGAGAT-3′

(SEQ ID NO;

     2); and

said second common sequence is the other of said P5 sequence and said P7 sequence.

44. The kit according to claim 31, wherein

said sequencing read-1 primer has the nucleotide sequence of ACACTCTTTCCCTACACGACGCTCTTCCGATCT (SEQ ID NO:

3); and

said sequencing read-2 primer has the nucleotide sequence of CTGGAGCTGTCTGCGACTTT (SEQ ID NO;

     4), wherein optionally at least one nucleotide is a locked nucleic acid (LNA) nucleotide.